Payment overview · 2025
General Payments
$2,306.77
114 reported records · 23 companies
Healthcare provider profile · identity verified
Nabil S Itani, DO
Allopathic & Osteopathic Physicians|Internal Medicine · TITUSVILLE, FL · NPI 1912009168
Verified facts
What the public records show
CMS Open Payments records show Nabil S Itani, DO received $2,306.77 in general payments during 2025 across 114 reported records.
ABBVIE INC. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Farxiga, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Paxlovid, Shingrix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HAVRIX as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Havrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 313 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $442.76 | 19.2% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $285.36 | 12.4% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $199.47 | 8.7% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $173.90 | 7.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $167.60 | 7.3% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $162.86 | 7.1% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $135.03 | 5.8% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $122.46 | 5.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $82.33 | 3.6% | 5 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $63.94 | 2.8% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $63.33 | 2.8% | 3 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $55.96 | 2.4% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $54.38 | 2.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $50.43 | 2.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $46.82 | 2.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $36.39 | 1.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.13 | 1.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $28.73 | 1.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.01 | 1.0% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.36 | 0.8% | 1 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $19.06 | 0.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.04 | 0.8% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.42 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,306.77 | 114 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $240.65 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $183.82 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $162.86 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $142.60 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $142.60 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $138.10 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $135.03 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $134.22 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $125.53 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $125.53 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $122.46 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $118.86 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $109.54 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $96.57 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $82.33 | 5 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $63.94 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $63.33 | 3 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $60.97 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.89 | 4 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $54.38 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $50.43 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $50.43 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $41.41 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $39.53 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $39.53 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.14 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $36.39 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.13 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $34.41 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $25.00 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.01 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 64 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 197 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 147 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 139 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 174 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 313 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 51 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 82 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
147 | 43 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 46 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | HAVRIX open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1190350374 |
Havrix · 2024 Exact normalized brand match · 1 Part D row |
46 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
82 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
200 | 37 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
139 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
174 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
313 | 73 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
64 | 64 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
197 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
51 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1135 | 288 |
| Amlodipine Besylate | Amlodipine Besylate | 940 | 257 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 875 | 277 |
| Lisinopril | Lisinopril | 791 | 217 |
| Losartan Potassium | Losartan Potassium | 788 | 224 |
| Atorvastatin Calcium | Atorvastatin Calcium | 725 | 218 |
| Alprazolam | Alprazolam | 645 | 116 |
| Gabapentin | Gabapentin | 608 | 160 |
| Omeprazole | Omeprazole | 594 | 168 |
| Metformin Hcl | Metformin Hcl | 579 | 166 |
| Metoprolol Succinate | Metoprolol Succinate | 455 | 131 |
| Tramadol Hcl | Tramadol Hcl | 390 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 386 | 121 |
| Zolpidem Tartrate | Zolpidem Tartrate | 386 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 382 | 128 |
| Escitalopram Oxalate | Escitalopram Oxalate | 364 | 95 |
| Hydrochlorothiazide | Hydrochlorothiazide | 333 | 99 |
| Meloxicam | Meloxicam | 324 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 96 |
| Ozempic | Semaglutide | 313 | 73 |
| Glimepiride | Glimepiride | 311 | 88 |
| Celecoxib | Celecoxib | 306 | 89 |
| Furosemide | Furosemide | 306 | 104 |
| Clopidogrel | Clopidogrel Bisulfate | 298 | 87 |
| Potassium Chloride | Potassium Chloride | 292 | 102 |
| Trazodone Hcl | Trazodone Hcl | 291 | 75 |
| Methylprednisolone | Methylprednisolone | 290 | 217 |
| Montelukast Sodium | Montelukast Sodium | 278 | 84 |
| Metoprolol Tartrate | Metoprolol Tartrate | 266 | 77 |
| Doxycycline Hyclate | Doxycycline Hyclate | 264 | 197 |
| Azithromycin | Azithromycin | 247 | 182 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 242 | 45 |
| Bupropion Xl | Bupropion Hcl | 238 | 51 |
| Simvastatin | Simvastatin | 226 | 59 |
| Atenolol | Atenolol | 220 | 59 |
| Prednisone | Prednisone | 218 | 149 |
| Lorazepam | Lorazepam | 217 | 44 |
| Metformin Hcl Er | Metformin Hcl | 214 | 68 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 200 | 37 |
| Eliquis | Apixaban | 197 | 46 |
| Diclofenac Sodium | Diclofenac Sodium | 185 | 82 |
| Fluoxetine Hcl | Fluoxetine Hcl | 184 | 52 |
| Doxepin Hcl | Doxepin Hcl | 181 | 61 |
| Duloxetine Hcl | Duloxetine Hcl | 178 | 52 |
| Buspirone Hcl | Buspirone Hcl | 176 | 48 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 174 | 144 |
| Donepezil Hcl | Donepezil Hcl | 174 | 39 |
| Mounjaro | Tirzepatide | 174 | 35 |
| Pregabalin | Pregabalin | 172 | 46 |
| Naloxone Hcl | Naloxone Hcl | 171 | 89 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 168 | 129 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 165 | 46 |
| Allopurinol | Allopurinol | 163 | 48 |
| Diazepam | Diazepam | 162 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 161 | 43 |
| Temazepam | Temazepam | 161 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 156 | 67 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 150 | 54 |
| Carvedilol | Carvedilol | 148 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 148 | 40 |
| Farxiga | Dapagliflozin Propanediol | 147 | 43 |
| Famotidine | Famotidine | 143 | 46 |
| Jardiance | Empagliflozin | 139 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 48 |
| Ezetimibe | Ezetimibe | 136 | 44 |
| Sertraline Hcl | Sertraline Hcl | 135 | 39 |
| Alendronate Sodium | Alendronate Sodium | 134 | 47 |
| Clonazepam | Clonazepam | 131 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 119 | 37 |
| Xarelto | Rivaroxaban | 115 | 34 |
| Levofloxacin | Levofloxacin | 110 | 82 |
| Valsartan | Valsartan | 110 | 37 |
| Memantine Hcl | Memantine Hcl | 108 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 100 | 31 |
| Ibuprofen | Ibuprofen | 96 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 96 | 23 |
| Glipizide Er | Glipizide | 95 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 94 | 23 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 91 | 24 |
| Fluconazole | Fluconazole | 90 | 46 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 26 |
| Mupirocin | Mupirocin | 89 | 65 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 86 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 85 | 24 |
| Ondansetron Odt | Ondansetron | 84 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 83 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 82 | 52 |
| Valacyclovir | Valacyclovir Hcl | 82 | 40 |
| Glipizide | Glipizide | 80 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 19 |
| Livalo | Pitavastatin Calcium | 80 | 27 |
| Topiramate | Topiramate | 80 | 19 |
| Methocarbamol | Methocarbamol | 79 | 36 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 22 |
| Cefdinir | Cefdinir | 75 | 61 |
| Paroxetine Hcl | Paroxetine Hcl | 73 | 16 |
| Naproxen | Naproxen | 72 | 27 |
| Aripiprazole | Aripiprazole | 69 | 12 |
| Clonidine Hcl | Clonidine Hcl | 68 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 68 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 15 |
| Baclofen | Baclofen | 65 | 18 |
| Mirtazapine | Mirtazapine | 65 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 65 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 64 | 64 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 63 | 21 |
| Finasteride | Finasteride | 63 | 22 |
| Januvia | Sitagliptin Phosphate | 63 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 62 | 12 |
| Promethazine Hcl | Promethazine Hcl | 61 | 16 |
| Sucralfate | Sucralfate | 61 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 58 | 16 |
| Trulicity | Dulaglutide | 58 | 12 |
| M-M-R Ii Vaccine | Measles,mumps,rubella Vacc/Pf | 57 | 44 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 56 | 11 |
| Spironolactone | Spironolactone | 55 | 21 |
| Nystatin | Nystatin | 54 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 39 |
| Nebivolol Hcl | Nebivolol Hcl | 53 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 53 | 14 |
| Estradiol | Estradiol | 52 | 16 |
| Rizatriptan | Rizatriptan Benzoate | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 52 | 13 |
| Paxlovid | Nirmatrelvir/Ritonavir | 51 | 50 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 49 | 47 |
| Primidone | Primidone | 49 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 47 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 15 |
| Havrix | Hepatitis A Virus Vaccine/Pf | 46 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 15 |
| Enalapril Maleate | Enalapril Maleate | 45 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 36 |
| Fenofibrate | Fenofibrate,micronized | 44 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 44 | 23 |
| Myrbetriq | Mirabegron | 43 | 17 |
| Novolog Flexpen | Insulin Aspart | 43 | 12 |
| Propranolol Hcl | Propranolol Hcl | 43 | 14 |
| Metronidazole | Metronidazole | 41 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 40 | 17 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 39 | 14 |
| Mometasone Furoate | Mometasone Furoate | 39 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 39 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 12 |
| Amoxicillin | Amoxicillin | 37 | 20 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 37 | suppressed |
| Dutasteride | Dutasteride | 37 | 13 |
| Warfarin Sodium | Warfarin Sodium | 37 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 14 |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 33 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 33 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Cephalexin | Cephalexin | 31 | 23 |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 19 |
| Linzess | Linaclotide | 31 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | suppressed |
| Colchicine | Colchicine | 26 | 15 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 13 |
| Bumetanide | Bumetanide | 25 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 16 |
| Lamotrigine | Lamotrigine | 25 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 25 | suppressed |
| Repaglinide | Repaglinide | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Epinephrine | Epinephrine | 24 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 23 | 21 |
| Digoxin | Digoxin | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Restasis | Cyclosporine | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Carbamazepine Er | Carbamazepine | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Progesterone | Progesterone, Micronized | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Androgel | Testosterone | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 13 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Menquadfi | Mening Vac A,c,y,w135,c-Tet/Pf | 11 | 11 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Skyclarys | Omaveloxolone | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,306.77 · 114 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, Briviact, CAMZYOS, CAPLYTA, CAPVAXIVE, CARTO 3, COMIRNATY, Cologuard Collection Kit, EDARBI, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, Leqembi, MAVYRET, MOUNJARO, NURTEC ODT, Nayzilam, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, Qelbree, REPATHA, Rybelsus, SHINGRIX, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error